GLP-2 Analogs
Class entry for analogs of the intestinotrophic hormone GLP-2, including the approved drug teduglutide for short bowel syndrome.
Overview
Glucagon-like peptide-2 (GLP-2) is a 33-amino-acid intestinotrophic hormone secreted by intestinal L cells. Its analogs form a genuine, clinically established drug class: teduglutide, a recombinant GLP-2 analog engineered for a longer half-life, is approved in several regions for short bowel syndrome. Additional long-acting investigational analogs, including apraglutide and glepaglutide, have reached late-stage clinical trials.
Mechanism
GLP-2 receptor activation promotes intestinal crypt-cell proliferation and villus growth, reduces epithelial apoptosis, and increases the absorptive surface and barrier function of the gut. These effects translate into improved nutrient and fluid absorption in patients with short bowel syndrome.
Dosing
Approved teduglutide is given as a daily subcutaneous injection with the regimen specified in its prescribing information. Investigational long-acting analogs are designed for less frequent administration; dosing in trials follows the published study protocols.
Expected Effects
- reduced dependence on parenteral nutrition and intravenous fluids in short bowel syndrome (randomized trial evidence)
- increased intestinal absorption and villus growth in preclinical and clinical studies
Side Effects & Tolerability
Common events in trials include injection-site reactions, abdominal pain, and gastrointestinal symptoms. Product labeling and surveillance guidance address a potential risk of accelerated growth of intestinal polyps or neoplasia, and endoscopic monitoring is recommended during treatment.
Storage
These are pharmaceutical products; storage and handling follow the manufacturer's label for each approved or investigational formulation.